Statins and cancer: Current and future prospects

Statins are inhibitors of 3-hydroxy-methylglutaryl (HMG) CoA reductase. They exhibit effects beyond cholesterol reduction, including anticancer activity. This review presents the effects of statins in vitro and their possible molecular anticancer mechanisms and critically discusses the data regardin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2012-11, Vol.324 (1), p.1-12
1. Verfasser:	Osmak, Maja
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals anticarcinogenic activity Antineoplastic Agents - pharmacology Bone marrow Breast cancer Cancer prevention Cancer treatment Cell Cycle Checkpoints Cholesterol Colorectal cancer Drug Resistance, Neoplasm drugs enzyme inhibitors Hematology, Oncology and Palliative Medicine Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Leukemia neoplasms Neoplasms - drug therapy Neoplasms - pathology Neoplasms - prevention & control Ovarian cancer Statins Stem cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Statins are inhibitors of 3-hydroxy-methylglutaryl (HMG) CoA reductase. They exhibit effects beyond cholesterol reduction, including anticancer activity. This review presents the effects of statins in vitro and their possible molecular anticancer mechanisms and critically discusses the data regarding the role of statins in cancer prevention. Finally, this review focuses on the use of statins combined with other chemotherapeutics to increase the effectiveness of cancer treatments. Despite rare and inconclusive clinical data, the preclinical results strongly suggest that such combined treatment could be a promising new strategy for the treatment of certain tumor types.
ISSN:	0304-3835 1872-7980
DOI:	10.1016/j.canlet.2012.04.011